Atea Pharmaceuticals reported a net loss of $32.2 million for the third quarter of 2026, an improvement from the $42.0 million loss in the prior year period. Total current assets decreased significantly from $311.0 million at year-end 2025 to $200.3 million as of September 30, 2026, primarily driven by a reduction in marketable securities used to fund operations.
Atea Pharmaceuticals reported Q3 2026 financial results and provided a clinical update on its Phase 3 C-BEYOND trial for Hepatitis C, which met its primary and secondary endpoints. The company also secured up to $200 million in non-dilutive funding from Hercules Capital and expects topline results from its Phase 3 C-FORWARD trial in early 2027.
Term
Q3 2026
“The C-BEYOND results are strong and reinforce our conviction that the regimen of BEM/RZR will deliver a differentiated profile, including high HCV cure rates, short treatment duration, a low risk of drug-drug interactions and no food effect, which we believe are critical to drive broad adoption of BEM/RZR in clinical practice by prescribers.”
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals
“We anticipate the upcoming topline Phase 3 results of C-FORWARD should further validate the potential of BEM/RZR, if approved, to be a new pan-genotypic treatment option for prescribers to treat people living with HCV.”
Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals